Table 2. Primary and First Secondary End Points.
In the CENTERSTONE phase 3b trial conducted over the 2019–2024 influenza seasons, baloxavir resulted in a significantly lower incidence of transmission of influenza virus from patients to household contacts than placebo. Full trial results: nej.md/4j78IZE
#MedSky #IDSky #IDThreads